Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-08 02:02 UTC

BIOMED PULSE

DAILY BRIEFING ON LONGEVITY, VIRUSES & NEW CURES

Tuesday, July 8, 2026

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now surpassed 1,460 confirmed cases and 452 deaths as of July 1, with the PARTNERS clinical trial opening patient enrolment in DRC on July 2 — the first-ever treatment trial for this strain. The overall mood is urgent but cautiously active: a PHEIC remains in force, new diagnostics are online, and science is finally catching up to a pathogen that has long lacked any approved therapy. [1] [2] [3]

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS — DRC AND UGANDA (PHEIC)

  • As of July 1, 2026, the DRC alone has recorded 1,460 confirmed cases and 452 deaths from Bundibugyo virus disease (BVD), with cross-border transmission ongoing in Uganda. [1]
  • WHO declared this outbreak a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, noting it does not yet meet criteria for pandemic emergency status. [4] [5]
  • Africa CDC and WHO jointly launched a continental preparedness and response plan on June 5, seeking to raise US$518 million to support African countries in containment. [6]
  • On June 17, WHO released its first-ever comprehensive clinical management guidelines covering all types of Ebola and Marburg viruses to standardize care at treatment centres. [7]
  • On July 2, the PARTNERS clinical trial opened enrolment for patients in DRC — the first scientific trial to evaluate any candidate treatments specifically for Bundibugyo virus disease. [2]
  • Also on July 2, WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing, detecting the virus via genetic material in blood samples. [3]
  • CDC has expanded enhanced Ebola airport screening beyond Washington-Dulles International to Atlanta's Hartsfield-Jackson airport as case counts climb. [8] [9]
  • CDC mobilised its international Ebola response on May 17 and has been issuing near-daily transcripts of briefings throughout June and into July. [10]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The fifth WHO Disease Outbreak News report (published July 2, 2026) on the Andes hantavirus (ANDV) outbreak linked to M/V Hondius confirms additional cases since the May 13 update.
  • The outbreak began May 2, 2026, aboard a cruise ship carrying 147 passengers and crew; WHO confirmed two laboratory cases early on, with several suspected cases in passengers from 23 countries.
  • CDC has continued issuing briefing transcripts through late June 2026 and confirmed the U.S. public risk remains extremely low.
  • WHO Director-General thanked the people of Tenerife for cooperation in safely disembarking more than 120 passengers from 23 countries during the response operation.

NIPAH VIRUS — INDIA AND BANGLADESH

  • On June 11, 2026, Kerala State Health Department confirmed one new laboratory-confirmed Nipah virus (NiV) case in Kozhikode district; the adult male presented with neurological symptoms.
  • Earlier in 2026, India reported two NiV-infected healthcare workers in West Bengal (January 26), and Bangladesh reported one case in Rajshahi Division (February 3), extending a pattern of endemic recurrence.

MPOX — RECOMBINANT STRAIN

  • WHO reported in February 2026 that two cases of a recombinant monkeypox virus (MPXV) strain comprising genetic elements of both clade Ib and clade IIb have been documented globally, a product of natural co-infection recombination.

YELLOW FEVER — GLOBAL

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections, continuing elevated transmission in the Americas that began in 2025.

WEST NILE VIRUS — UNITED STATES

  • CDC issued a July 1 advisory warning of an early and record-setting West Nile virus season in the United States, urging the public to use mosquito repellent through the July 4th Independence Day holiday weekend.

E. COLI — FROZEN BLUEBERRIES, UNITED STATES

  • CDC posted a food safety alert on July 7, 2026, warning of an E. coli outbreak linked to frozen blueberries; a product recall is in effect and consumers are urged not to eat recalled items.

DRUG-RESISTANT BACTERIA — UNITED STATES

  • A CDC report published September 2025 found a dramatic increase in dangerous drug-resistant bacteria nationally, underscoring antibiotic stewardship urgency heading into 2026.

🧬 LONGEVITY & AGING

DELIRIUM AS A PATHWAY FROM INFECTION TO DEMENTIA

  • Two commentaries published in Lancet Healthy Longevity (Sipilä and Kivimäki; Penfold, Jiwaji, and MacLullich) argue that delirium during or after severe infection may be a key mechanistic bridge linking acute illness to subsequent dementia, suggesting a new prevention target.

KAEMPFEROL FROM MORINGA AND CELLULAR SENESCENCE

  • A study published in Toxicology Reports (Iorjiim et al., June 25, 2026) found that kaempferol extracted from Moringa oleifera increases lifespan and reduces efavirenz-induced functional senescence in Drosophila melanogaster, pointing to flavonoid-based anti-aging strategies.

NAD-PLUS RESTORATION FOR AGED BONE REPAIR

  • Researchers published in Bioactive Materials (Jiang et al., June 27, 2026) report that a senescent metabolism-modulating hierarchical scaffold restores NAD-plus homeostasis and redox balance in aged bone tissue, improving bone repair outcomes in a model of age-related deterioration.

CHONDROCYTE SENESCENCE MODULE — NINE-GENE SIGNATURE

  • A study in Regenerative Therapy (Alemujiang et al., June 13, 2026) identified a conserved nine-gene decline module in long-term expandable auricular chondrocytes, operating independently of classic senescence markers, revealing a new mechanism underlying age-related tissue dedifferentiation.

INSULIN RESISTANCE AND MILD COGNITIVE IMPAIRMENT

  • A Finnish cohort study in Scandinavian Journal of Primary Health Care (Rotonen et al., June 23, 2026) found significant associations between insulin resistance and mild cognitive impairment during aging, adding metabolic dysfunction to the list of modifiable dementia risk factors.

CHRONIC KIDNEY DISEASE, MULTIMORBIDITY, AND MORTALITY

  • A multicentre UK cohort study (NURTuRE-CKD, published in Annals of Medicine, June 23, 2026) found that accumulating multiple long-term conditions sharply raises mortality, kidney failure progression, and health-related quality of life decline among people with chronic kidney disease.

METABOLIC LIVER DISEASE AND TOBACCO — GLOBAL BURDEN

  • A Europe PMC study in Journal of Diabetes and Metabolic Disorders (Xu et al., July 3, 2026) quantified the global burden of metabolic dysfunction-associated steatotic liver disease attributable to tobacco from 1990 to 2023 and projected trends to 2038, finding tobacco a persistently underappreciated driver.

PHYSICAL ACTIVITY RESTRICTION AND CEREBROVASCULAR MORTALITY — JAPAN

  • An ecological panel study across 47 Japanese prefectures (2013 to 2022) in Dialogues in Health (Kimura, June 11, 2026) found that structural physical activity restriction was associated with higher cerebrovascular and diabetes mortality and greater long-term care intensity, with a COVID-19 counterfactual analysis included.

INTRINSIC CAPACITY AND RESILIENCE IN OLDER ADULTS — TAIWAN

  • A new prospective observational cohort study at ClinicalTrials.gov (NCT07687563) is enrolling community-dwelling middle-aged and older adults in Taiwan to track how intrinsic capacity, resilience, and meaning in life change over time in community center participants.

💊 NEW CURES & APPROVALS

  • RINVOQ (upadacitinib), AbbVie: a supplemental approval action (SUPPL AP) has been recorded on openFDA under NDA211675 for this JAK1 inhibitor used across multiple inflammatory conditions.
  • RINVOQ LQ (upadacitinib liquid formulation), AbbVie: a separate supplemental approval under NDA218347 extends the upadacitinib portfolio with a liquid formulation, broadening patient access.
  • CIBINQO (abrocitinib), Pfizer: supplemental approval under NDA213871 for this JAK1 inhibitor indicated for moderate-to-severe atopic dermatitis in adults.
  • KISQALI (ribociclib succinate), Novartis: supplemental approval under NDA209092 for this CDK4/6 inhibitor used in hormone receptor-positive, HER2-negative breast cancer.
  • KISQALI FEMARA CO-PACK (ribociclib plus letrozole), Novartis: supplemental approval under NDA209935 for the co-packaged CDK4/6 inhibitor and aromatase inhibitor combination regimen for breast cancer.
  • FETROJA (cefiderocol sulfate tosylate), Shionogi: supplemental approval under NDA209445 for this siderophore cephalosporin antibiotic targeting drug-resistant Gram-negative bacteria.
  • MAYZENT (siponimod), Novartis: supplemental approval under NDA209884 for this sphingosine 1-phosphate receptor modulator indicated for secondary progressive multiple sclerosis.
  • RIVAROXABAN, Mankind Pharma: original approval (ORIG AP) under ANDA220874 for a generic formulation of this Factor Xa inhibitor anticoagulant.
  • ADAPALENE, Unique: original approval under ANDA219565 for this retinoid topical agent used in acne treatment.
  • METFORMIN HYDROCHLORIDE and SITAGLIPTIN PHOSPHATE, Zydus Pharms USA: original tentative approval (ORIG TA) under ANDA208535 for this generic type 2 diabetes combination tablet.

🧪 CLINICAL TRIALS

PARTNERS TRIAL — BUNDIBUGYO VIRUS TREATMENTS, DRC

  • WHO announced on July 2, 2026, that the PARTNERS clinical trial has opened patient enrolment in DRC to evaluate the first candidate therapeutics ever tested against Ebola disease caused by Bundibugyo virus. [2]

TRONTINEMAB FOR EARLY ALZHEIMER'S DISEASE

  • A phase trial listed as NCT07170150 on ClinicalTrials.gov is assessing the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease, ranging from mild cognitive impairment to mild dementia, updated July 7, 2026.

ZONGERTINIB (BEAMION PANTUMOR-1) FOR HER2-ALTERED ADVANCED CANCERS

  • Trial NCT06581432 is evaluating zongertinib, an oral HER2-targeting tyrosine kinase inhibitor, in adults aged 18 and over with advanced solid tumors bearing HER2 alterations who have failed prior therapy; updated July 7, 2026.

PACRITINIB FOR MYELODYSPLASTIC SYNDROMES

  • Trial NCT06303193 is studying pacritinib, a kinase inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in adults and pediatric patients aged 12 and older with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms; updated July 7, 2026.

FOSTAMATINIB TO PREVENT LUNG TRANSPLANT REJECTION (SIMILAR TRIAL)

  • Trial NCT06948097 is evaluating fostamatinib, a Syk kinase inhibitor, for safety and tolerability in lung transplant recipients who develop donor-specific antibodies — a key driver of chronic rejection and reduced median survival of six to seven years post-transplant.

CANCER LYSATE VACCINE WITH IL-15 SUPER-AGONIST N-803 FOR NSCLC

  • Trial NCT05642195 is testing a cancer lysate vaccine combined with Montanide ISA-51 VG adjuvant with or without N-803 (an IL-15 super-agonist) as adjuvant therapy for PD-L1-negative non-small cell lung cancer following surgery; updated July 7, 2026.

BLENDED BADUANJIN EXERCISE AND GREEN TEA FOR DEPRESSION IN OLDER ADULTS

  • Trial NCT07687940 is assessing feasibility and effects of combining traditional Baduanjin qigong exercise with green tea consumption on depressive symptoms, gut microbiota, and quality of life in older adults; listed July 7, 2026.

LAVENDER AROMATHERAPY FOR MILD COGNITIVE IMPAIRMENT

  • Trial NCT07688382 is evaluating lavender aromatherapy effects on memory, executive function, language, attention, visuospatial ability, and anxiety in older adults with mild cognitive impairment; listed July 7, 2026.

LIDOCAINE-TETRACAINE CREAM FOR NEUROPATHIC PAIN IN OLDER ADULTS

  • Trial NCT07396129 is testing a high-dose topical lidocaine-tetracaine cream for chronic peripheral neuropathic pain specifically in older adults who have not responded to standard treatments; updated July 7, 2026.

ELECTRONIC GERIATRIC ASSESSMENT PLATFORM FOR OLDER CANCER PATIENTS

  • Trial NCT04824859 (eGAP) is assessing the feasibility and usability of a digital geriatric assessment platform for 50 older patients with cancer, their caregivers, and oncology teams; updated July 7, 2026.

📢 PUBLIC HEALTH

IMMUNIZATION SCHEDULE UPDATES — UNITED STATES

  • CDC updated its child and adult immunization schedules in October 2025 to apply individual-based decision-making for COVID-19 vaccination and introduced standalone varicella vaccination for toddlers.
  • ACIP voted in December 2025 to allow individual-based decision-making for hepatitis B vaccination for infants born to hepatitis B virus-negative mothers; CDC formally adopted this in December 2025.

SALMONELLA OUTBREAKS — MULTIPLE ONGOING, UNITED STATES

  • As of late May 2026, CDC flagged a growing cluster of Salmonella outbreaks linked to moringa leaf products across multiple states; extensively drug-resistant strains have been confirmed in some cases.
  • CDC announced in April 2026 that 34 people across 13 states are sick with the same Salmonella strain linked to backyard poultry, rising to 150 additional cases by May 14, with over a quarter of cases in children under five years old.

LISTERIA — REQUESÓN AND SOFT RICOTTA CHEESE

  • CDC warned on June 5, 2026, of a Listeria monocytogenes outbreak linked to requesón and soft ricotta cheese; consumers are advised to check and discard affected products.

NEW WORLD SCREWWORM — UNITED STATES

  • CDC activated its Emergency Operations Center on June 12, 2026, for a New World Screwworm (Cochliomyia hominivorax) response — a parasitic fly larvae that can infect open wounds in mammals and humans.

INFANT BOTULISM — POWDERED FORMULA

  • CDC issued a June 13, 2026, outbreak alert urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula, linked to confirmed infant botulism cases.

UNSAFE FOOD — GLOBAL MORTALITY ESTIMATE

  • WHO released new estimates on June 4, 2026, calculating that unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide, with children under five years facing nearly three times the risk of food-borne illness compared to older children and adults.

CDC TRAVELER GENOMIC BIOSURVEILLANCE

  • CDC announced January 30, 2026, that its Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants, strengthening early detection of novel pathogens at U.S. borders.

This briefing is informational only and does not constitute medical advice. Always consult a licensed healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Patient enrolment begins in a scientific trial to identify the… — WHO News
  3. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  4. Epidemic of Ebola Disease caused by Bundibugyo virus in the De… — WHO News
  5. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  6. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  7. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  8. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  10. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260708-02-v21 · 2026-07-08 02:02 UTC · pulse.uzylab.com

Read next